期刊
NEPHROLOGY DIALYSIS TRANSPLANTATION
卷 36, 期 6, 页码 966-974出版社
OXFORD UNIV PRESS
DOI: 10.1093/ndt/gfaa203
关键词
activin A; chronic kidney disease; CKD-MBD; fibrosis; vascular calcification
Chronic kidney disease-mineral bone disorder (CKD-MBD) is closely linked to elevated cardiovascular morbidity and mortality in CKD patients. Emerging evidence suggests that pathways like canonical Wnt signaling are activated early in CKD and may play a role in the development of adynamic bone disease and vascular calcification. Studies show that the progression of vascular calcification parallels changes in bone mineral density and turnover, indicating shared pathways between bone and arterial mineralization. Further research is needed to identify new mediators involved in CKD-MBD pathogenesis and develop more effective therapeutic strategies.
Chronic kidney disease-mineral bone disorder (CKD-MBD) plays a pivotal role in the excess of cardiovascular morbidity and mortality associated with CKD. There is now a growing awareness that pathways involved in CKD-MBD, like canonical Wnt signalling, are activated from the earliest stages of CKD, playing a role in the development of adynamic bone disease with unknown consequences on vasculature. These changes occur before the classic changes in mineral metabolism: secondary hyperparathyroidism, calcitriol deficiency and hyperphosphataemia. Furthermore, vascular calcification is frequently associated and evolves with decreased bone mineral density and deranged bone turnover, while bone and arterial mineralization share common pathways. Therefore, results of clinical trials focused on mineral bone disorder, aimed at preserving bone and cardiovascular health, are considered unsatisfactory. In order to identify more effective therapeutic strategies, it is necessary to clarify the pathways modulating the cross-talk between bone and vasculature and identify new mediators involved in the pathogenesis of CKD-MBD. Much attention has been paid recently to the role of the transforming growth factor-beta superfamily members in renal disease, and in particular of activin A (ActA). Preclinical studies demonstrate an upgrade of ActA signalling in kidney, skeleton, vasculature and heart during CKD. This supports the idea that an endocrine factor produced in the kidney during renal disease, in addition to promoting the progression of kidney damage, deranges other organs' homoeostasis and participates in CKD-MBD. In this review, we analyse the contribution of ActA to kidney fibrosis and inflammation as well as its role in the development of CKD-MBD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据